AireHealth, a digital health company empowering and improving healthy living through affordable treatments, symptom tracking, and early detection of respiratory conditions, announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its connected nebulizer. The device is a portable, electronic vibrating mesh nebulizer designed to nebulize liquid medications for inhalation by a patient in and out of the home. The nebulizer will be marketed and sold under the brand name VitalMed.
 
Early next year, the nebulizer will seamlessly connect to VitalCompanion, AireHealth’s new diary companion app designed to help patients track symptoms, receive support for medication adherence and enable real-time connections to their providers. In 2021, AireHealth will also add VitalCapacity, a connected spirometer, to its VitalBreath respiratory care platform.
 
“Consumers facing chronic respiratory issues require care, resources and tools that integrate with their day-to-day lives, which is why the development of a connected platform to comprehensively address their needs is so vital,” said Rebecca Shanahan, AireHealth’s interim CEO. “AireHealth is pleased to have received 510(k) clearance of our connected nebulizer from the FDA, which will support the creation of an overall ecosystem of connected solutions to treat patients with respiratory conditions.”
 
AireHealth recently completed an acquisition of BreathResearch to address the growing challenges in respiratory illness that cost more than $130 billion per year, and are the cause of nearly 50 deaths per 100,000 people. The acquisition has positioned AireHealth to integrate data collection and analysis capabilities into its connected respiratory care platform. By tracking symptoms, status, decline, interventions and outcomes, AireHealth can build data sets for clinical benchmarks, improve early detection of respiratory diseases and reduce high costs.